Board of Emcure Pharmaceuticals approves draft scheme of amalgamation
(12 Oct 2026)

Back
The board of Emcure Pharmaceuticals at its meeting held on 12 October 2026 has approved the draft Composite Scheme of Amalgamation amongst Zuventus Healthcare and Emcutix Biopharmaceuticals (collectively referred to as the Transferor Companies) both being wholly owned subsidiaries of the Company with Emcure Pharmaceuticals (Transferee Company) and their respective shareholders and creditors pursuant to Sections 230 to 232 and other applicable provisions of the Companies Act, 2013 (Scheme).
BSE Delayed data sourced at 5 mins : www.bseindia.com | NSE Delayed data sourced at 15 mins : www.nseindia.com

Copyright © 2026 Arihant Capital Markets Ltd. All rights Reserved.

Designed, Developed and Content powered by CMOTS InfoTech (ISO 9001:2015 & ISO/IEC 27001:2022 Certified)

x
  • QR-CodeNew